CytoHub Inc.
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Cardiovascular
CytoHub: Crafting cells for cures
CytoHub is a cell therapy and human-tissue engineering company built on human iPSC-derived developmental biology. Our lead program, HeartReady™, is an iPSC-derived cardiac cell therapy in early-stage preclinical development for ischemic heart failure — designed to restore the heart muscle lost to ischemic injury. It is being advanced through Cardia Therapeutics, a separately capitalized subsidiary.
The same biology powers two revenue-generating platforms: CardioVive™, a human "mini-heart" organoid model for cardiac pharmacology, safety, and disease modeling, and BioEngineAI™, our AI and data layer for predictive analytics and manufacturing automation — serving biopharma and research partners while sharpening HeartReady's path to the clinic.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
(HeartReady™): Platform-enabled, hypo-immune cardiac cell therapy
CEO
Rajib Biswas, PhD
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Two to three years.
What is your next catalyst (value inflection) update?
IND Submission
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}